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httpMortality rates and mortality predictors in patients
with symptomatic peripheral artery disease stratiﬁed
according to age and diabetes
Thomas Mueller, MD,a Franz Hinterreiter, MD,b Christian Luft, MD,c Werner Poelz, PhD,d
Meinhard Haltmayer, MD,a and Benjamin Dieplinger, MD,a Linz, Austria
Objective: Atherosclerotic peripheral arterial disease (PAD) is one of the most prevalent, morbid, and mortal diseases. The
aim of this study was to evaluate mortality rates of patients with atherosclerotic PAD stratiﬁed according to age and
diabetes and to determine predictors of death.
Methods:We studied 487 patients with symptomatic PAD consecutively admitted to the hospital. This cohort included the
following four patient subgroups: (1) 216 patients with PAD <75 years of age without diabetes mellitus; (2) 115 patients
with PAD <75 years of age with diabetes mellitus; (3) 102 patients with PAD$75 years of age without diabetes mellitus;
and (4) 54 patients with PAD $75 years of age with diabetes mellitus. Control subjects without atherosclerotic disease
were matched to the patients with PAD in a 1:1 design by sex, age (62 years), and diabetes mellitus status. Outcome
measure was all-cause mortality at 5 years.
Results: Mortality rates at 5 years were 10% in nondiabetic patients with PAD <75 years of age (vs 5% in control subjects;
risk ratio [RR], 2.15; 95% conﬁdence interval [CI], 1.60-4.34); 23% in diabetic patients with PAD <75 years of age (vs
7% in control subjects; RR, 3.53; 95% CI, 1.80-6.91); 38% in nondiabetic patients with PAD $75 years of age (vs 22% in
control subjects; RR, 2.08; 95% CI, 1.26-3.44); and 52% in diabetic patients with PAD $75 years of age. Applying
multivariate Cox proportional hazards regression analyses (with cardiovascular risk factors, coexisting atherosclerotic
disease, clinical stage of PAD, and several biochemical markers as predictor variables), we found the following inde-
pendent predictors of outcome: in the 216 nondiabetic patients with PAD <75 years of age, high-sensitivity C-reactive
protein (hs-CRP) (RR, 3.04; 95% CI, 1.48-6.26); in the 115 diabetic patients with PAD <75 years of age, amino-terminal
proeB-type natriuretic peptide (NT-proBNP) (RR, 2.63; 95% CI, 1.65-4.19); in the 102 nondiabetic patients with PAD
$75 years of age, critical limb ischemia (RR, 3.70; 95% CI, 1.82-7.52) and NT-proBNP (RR, 1.93; 95% CI, 1.32-2.82);
and in the 54 diabetic patients with PAD$75 years of age, hs-CRP (RR, 2.61; 95% CI, 1.45-4.67) and NT-proBNP (RR,
3.31; 95% CI, 1.96-5.60).
Conclusions: Mortality rates at 5 years varied considerably among patients with PAD stratiﬁed according to age and
diabetes. Predictors of death differed among the four patient subgroups in this study and included critical limb ischemia,
hs-CRP, and NT-proBNP. Our results might help to develop future strategies for optimized treatment of hospitalized
patients with symptomatic PAD. (J Vasc Surg 2014;59:1291-9.)Atherosclerotic peripheral artery disease (PAD) is a
progressive condition characterized by stenoses and occlu-
sions in the arteries of the legs.1,2 It can be asymptomatic
or symptomatic.1,2 Symptomatic PAD ranges in severity
from claudication to critical limb ischemia.1,2 Advanced
age, diabetes, and smoking are considered the strongest
risk factors for PAD.2,3 Other classic risk factors include
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://dx.doi.org/10.1016/j.jvs.2013.11.063Atherosclerotic PAD is one of the most prevalent,
morbid, and mortal diseases.4 Recently, a conservative esti-
mate on the global burden of PAD came up with more
than 200 million individuals with PAD worldwide.3 PAD
is a sign of systemic atherosclerosis in the population
>55 years of age1,2 and has thus been gaining recognition
as a severe cardiovascular disorder.2-6 In addition to func-
tional impairment and related effects on quality of life,
patients with PAD are at signiﬁcantly higher risk of
subsequent myocardial infarction, ischemic stroke, and
death than are individuals without PAD.1-6
In the population with atherosclerotic vascular disease,
risk management is a major health challenge.7 Current sec-
ondary risk prediction in patients with PAD is primarily
based on classic cardiovascular risk factors. Risk stratiﬁca-
tion in patients with PAD is, however, further inﬂuenced
by several other factors, such as coexisting atherosclerotic
burden, hemodynamic severity of PAD, and the clinical
stage of the disease.7 Moreover, strategies to improve risk
assessment should also involve the approach of the use of
biochemical markers reﬂecting different elements of the
pathophysiology of vascular disease.5,7,81291
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mortality rates vary in patients with PAD with and without
diabetes mellitus according to different age groups and
whether diverse risk factors contribute to mortality in
different ways in such subgroups of patients with PAD.
Therefore, the aim of this study was (1) to evaluate mortal-
ity rates of patients with atherosclerotic PAD stratiﬁed
according to age and diabetes; and (2) to determine
predictors of death, including classic cardiovascular risk fac-
tors, coexisting atherosclerotic diseases, clinical stage of
PAD, and several biochemical markers.
METHODS
Study cohort. For this work, the data from the Linz
Peripheral Arterial Disease (LIPAD) study were used.9,10
This study was prospectively designed to evaluate bio-
logic and genetic markers for PAD by use of a case-control
design and to determine the predictive value of those same
markers on long-term outcome of patients with PAD.9,10
The local ethics committee approved the study protocol
in accordance with the Declaration of Helsinki. All study
participants gave informed consent. We took a thorough
history in patients with PAD and control subjects.
Furthermore, in all patients and control subjects, we carried
out Doppler segmental blood pressure of the lower limbs,
including continuous-wave spectral analysis and resting
ankle-brachial index (ABI) measurements, as well as color
duplex ultrasound scanning of the carotid bifurcation and
the internal carotid artery as described.9,11,12 In addition to
these measurements, we performed contrast intra-arterial
aortofemoral angiography in the patients to afﬁrm the
presence of PAD and to characterize the site and extent of
wall changes. As recommended, all participants of the
LIPAD study underwent careful evaluation for existing risk
factors of atherosclerotic disease and of comorbidities.13
Comprehensive information on the LIPAD study is given
in previous publications on this cohort.9,10,14-17
Deﬁnitions. Symptomatic PAD was deﬁned as Ruth-
erford stages 1-6.13 Coronary artery disease (CAD) was
deﬁned as previous percutaneous transluminal coronary
angioplasty or coronary bypass surgery, as remote
myocardial infarction or acute coronary syndrome by his-
tory, or as occult myocardial infarction by electrocardiog-
raphy.9 Cerebrovascular disease (CVD) was deﬁned as the
history of stroke with permanent neurological deﬁcit or as
the history of transient or temporary stroke.9 Arterial hy-
pertension was deﬁned as systolic blood pressure$145 mm
Hg or diastolic blood pressure $90 mm Hg or the use of
any antihypertensive medication.9 Diabetes mellitus was
deﬁned as fasting blood glucose levels $126 mg/dL or the
use of any glucose-lowering medication.9
Patients with PAD. FromApril 2000 toApril 2002,we
consecutively enrolled patients with symptomatic chronic
atherosclerotic PAD admitted to the Konventhospital Barm-
herzigeBrueder, Linz,Austria.9 At this time, it was customary
in Austrian health care to evaluate all possible symptomatic
patients with PAD as inpatients. The patients of this single-
center study were enrolled at admittance to the hospital.This implies that we obtained baseline data before any PAD-
speciﬁc treatment and/or modiﬁcation of drug therapy dur-
ing this index hospitalization. We admitted the patients for
diagnostics and treatment of PAD, and, at the time of
enrollment, none had acute coronary syndrome or angina,
acute stroke, or acute transient or temporary stroke.Exclusion
criteria were the history or presence of any malignancy, acute
PAD, and PAD caused by nonatherosclerotic causes.9 The
ﬁnal study cohort included 487 consecutive subjects with
symptomatic PAD.9 All patients with PAD were white. This
series of patients included the following four patient sub-
groups9: (1) 216 patients with PAD<75 years of age without
diabetesmellitus; (2) 115 patients with PAD<75 years of age
with diabetes mellitus; (3) 102 patients with PAD$75 years
of agewithoutdiabetesmellitus; and (4)54patientswithPAD
$75 years of age with diabetes mellitus.
Healthy control subjects. From January 2001 to July
2004, we recruited control subjects matched to the patients
with PAD in a 1:1 design by age (62 years), sex, and dia-
betes mellitus status. All control subjects were patients of
the Konventhospital Barmherzige Brueder, Linz, Austria.
We admitted the control subjects for the treatment of minor
problems with health such as vertebragenic pain, cataract
surgery, and nonvascular surgery (eg, varicose vein extir-
pation, herniotomy).9 All control subjects were in good
health and had the following characteristics9: no history/
presence of malignant disease; no CAD; no CVD; no clin-
ical evidence of PAD by physical examination or history;
ABI $1.0; no pathological patterns of pulse waves in the
legs by continuous-wave spectral analysis; no previous
stenting or vascular surgery of the internal carotid arteries;
no stenosis of the internal carotid arteries >50%; and no
history of venous thromboembolism.9 The cohort of con-
trol subjects comprised 433 individuals without any relevant
atherosclerotic disease9: (1) 216 nondiabetic control sub-
jects matched to the 216 patients with PAD <75 years
without diabetes; (2) 115 diabetic control subjects matched
to the 115 patients with PAD <75 years with diabetes; and
(3) 102 nondiabetic control subjects matched to the 102
patients with PAD $75 years of age without diabetes.
Given our stringent selection criteria for control subjects, it
is conceivable that we were not able to recruit adequate
control subjects (ie, diabetic individuals $75 years of age
without any relevant atherosclerotic disease) for the 54
patients with PAD$75 years of age with diabetes mellitus.9
Biochemical analyses. After overnight fasting, blood
was collected from participants at admittance to the hospital
bymeans of venipuncture. Creatinine, lipid proﬁles, glucose,
glycohemoglobin A1c, adiponectin, total homocysteine,
high-sensitivity C-reactive protein (hs-CRP), the amino-
terminal fragment of the B-type natriuretic peptide pro-
hormone (NT-proBNP), and pregnancy-associated plasma
protein-A were analyzed with the use of appropriate assays.
Allmethods have been described in detail previously, and the
rationale for selecting all these parameters have been
described in the respective papers.9,10,14-17 Estimated
glomerular ﬁltration rate was calculated by means of the
Modiﬁcation of Diet in Renal Disease formula.18
Table I. Baseline characteristics of 487 consecutive patients with symptomatic PAD according to the four patient groups
Variables
Nondiabetic patients
with PAD <75 years
of age (n ¼ 216)
Diabetic patients
with PAD <75 years
of age (n ¼ 115)
Nondiabetic patients
with PAD $75 years
of age (n ¼ 102)
Diabetic patients
with PAD $75 years
of age (n ¼ 54)
Patient age, years 64 (57-70) 65 (59-70) 80 (78-82) 79 (77-82)
Male sex 170 (79) 87 (76) 49 (48) 34 (63)
Body mass index, kg/m2 26 (24-29) 28 (25-30) 25 (23-27) 25 (23-28)
Arterial hypertension 96 (44) 83 (72) 72 (71) 45 (83)
Cardiovascular comorbiditya 70 (32) 61 (53) 49 (48) 32 (59)
Current smokingb 122 (57) 50 (44) 21 (21) 7 (13)
PAD-relevant data at enrollment
into the LIPAD study
Critical limb ischemia 20 (9) 37 (32) 17 (17) 20 (37)
Claudication 196 (91) 78 (68) 85 (83) 34 (63)
Resting ABI, mm Hg/mm Hg 0.64 (0.50-0.78) 0.65 (0.53-0.81) 0.58 (0.38-0.79) 0.57 (0.50-0.78)
Duration of symptomatic PAD, years 2.4 (1.1-5.5) 3.3 (1.5-7.0) 2.7 (1.0-5.8) 3.1 (1.4-5.3)
History of PAD-speciﬁc interventionc 82 (38) 54 (67) 40 (39) 24 (44)
Type of PAD-speciﬁc treatment during
index hospitalization
Vascular surgery 50 (23) 20 (17) 19 (19) 2 (4)
Vascular surgery and PTA 7 (3) 3 (3) 5 (5) 5 (8)
Vascular surgery and amputation 1 (1) 2 (2) 0 2 (4)
PTA 95 (44) 39 (34) 31 (30) 15 (29)
PTA and amputation 0 1 (1) 1 (1) 1 (2)
Amputation 2 (1) 6 (5) 0 3 (5)
Conservative treatment 61 (28) 44 (38) 46 (45) 26 (48)
Biochemical parameters at enrollment
into the LIPAD study
Creatinine, mg/dL 1.0 (0.8-1.1) 1.0 (0.8-1.2) 1.0 (0.9-1.2) 1.1 (0.9-1.4)
eGFR, mL/min/1.73 m2 79 (69-90) 73 (60-88) 64 (57-77) 62 (51-76)
LDL-cholesterol, mg/dL 155 (131-184) 136 (104-169) 146 (124-171) 124 (106-150)
HDL-cholesterol, mg/dL 50 (40-59) 41 (34-54) 58 (47-70) 46 (35-58)
Triglycerides, mg/dL 139 (101-208) 147 (115-219) 115 (93-164) 113 (85-186)
Fasting glucose, mg/dL 96 (89-105) 170 (133-206) 95 (88-101) 147 (116-187)
Glycohemoglobin A1c, % 5.8 (5.5-6.2) 8.0 (7.1-9.2) 5.9 (5.5-6.2) 7.6 (7.1-8.6)
Adiponectin, mg/mL 9.1 (6.0-12.2) 8.4 (5.8-12.8) 13.2 (9.0-17.0) 10.3 (6.9-20.7)
Total homocysteine, mmol/L 15.1 (12.8-19.4) 15.2 (12.5-20.2) 19.2 (15.8-24.4) 18.3 (15.2-24.7)
hs-CRP, mg/L 4.2 (1.8-8.0) 4.7 (1.9-12.5) 3.2 (1.6-9.0) 6.3 (2.1-18.0)
NT-proBNP, ng/L 103 (44-305) 225 (69-793) 344 (152-877) 496 (232-1262)
PAPP-A, mIU/L 0.79 (0.53-1.23) 0.77 (0.49-1.24) 0.86 (0.56-1.34) 0.87 (0.59-1.39)
ABI, Ankle-brachial index; CAD, coronary artery disease; CVD, cerebrovascular disease; eGFR, estimated glomerular ﬁltration rate; HDL, high-density li-
poprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; LIPAD, Linz Peripheral Arterial Disease; NT-proBNP, amino-terminal
pro-Betype natriuretic peptide; PAPP-A, pregnancy-associated plasma protein-A; PAD, peripheral arterial disease; PTA, percutaneous transluminal angio-
plasty with or without stenting.
Data are given as number (%) or median (25th-75th percentiles).
aCardiovascular comorbidity was deﬁned as having CAD or CVD or both.
bCurrent smoking was deﬁned as any amount of tobacco use, including abstinence less than 1 year.
cHistory of PAD-speciﬁc intervention before index hospitalization was deﬁned as at least one of the following: vascular surgery, PTA, or amputation.
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present work was all-cause mortality at 5 years. Mortality
data of the cases and control subjects including date of
death and cause of death were obtained from the Austrian
Death Registry.10 All 487 patients with PAD and all 433
control subjects completed follow-up, and the observation
period for each of them was appointed to 5 years (ie,
exactly 1825 days from the time of enrolment) or until
death if it occurred earlier.10 The results of adiponectin,
hs-CRP, NT-proBNP, and pregnancy-associated plasma
protein-A measurements were not available for the
attending physicians and vascular surgeons during entire
follow-up.
Statistical analysis. Our data were analyzed with
the use of MedCalc 10.0.0.0 (MedCalc Software, Ostend,Belgium) and SPSS 13.0 (SPSS Inc, Chicago, Ill). Contin-
uous variables are given as median (interquartile range)
unless otherwise stated. Kaplan-Meier estimates of the dis-
tribution of times from baseline to death were computed,
and a log rank test for trend was used to compare the survival
curves of the four patient subgroups. We further performed
log rank-tests to compare the survival curves of the patient
groups with the corresponding control subjects.
Univariate and multivariate Cox proportional hazards
regression analyses were used to analyze the effect of
several predictor variables on survival in each of the four pa-
tient subgroups. Continuous variables were not normally
distributed and were thus normalized by log transforma-
tion. Risk ratios (RRs) refer to a 1-standard deviation in-
crease in log-transformed values. Because of the limited
Fig 1. Kaplan-Meier plot shows survival in 487 consecutive patients with symptomatic peripheral arterial disease
(PAD) according to the four patient groups.
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variate RR were calculated with Cox proportional hazards
regression analysis by means of a stepwise forward approach
(ie, signiﬁcant variables were entered sequentially). For the
multivariate Cox proportional hazards regression analyses,
a stepwise entry limit of P < .01 was used instead of
P < .05 because we performed one Cox regression
analysis for each of the four patient groups; thus, we
adequately corrected our multivariate analyses for multiple
comparisons.
RESULTS
The LIPAD cohort (n ¼ 487) included 340 male
(70%) and 147 female (30%) subjects with symptomatic
PAD. The overall median age was 70 years (range, 38-94
years). At admission to the hospital, 94 patients had critical
limb ischemia (19%) and 393 patients had claudication
(81%). Of the 94 patients with critical limb ischemia, 17
patients had ischemic rest pain and 77 patients had minor
or major tissue loss; 153 patients had CAD (31%) and 99
had CVD (20%), yielding 212 patients with cardiovascular
comorbidity (44%). The LIPAD study included 200 sub-
jects with a history of PAD-speciﬁc intervention before
index hospitalization, which was deﬁned as at least one of
the following: vascular surgery, percutaneous transluminal
angioplasty with or without stenting, or amputation; 177
patients received conservative treatment during the index
hospitalization and 310 had PAD-speciﬁc interventions(vascular surgery, percutaneous transluminal angioplasty,
or amputation); four patients died in the hospital. Medical
therapy at admission to the hospital and at demission from
index hospitalization has been reported in detail previ-
ously.10 Table I shows the baseline characteristics of the
487 consecutive patients with symptomatic PAD stratiﬁed
according to age and diabetes into the four patient
subgroups.
Of the 487 patients with PAD, 114 individuals died
(23%) and 373 individuals survived (77%) during follow-
up. Fig 1 demonstrates survival of the 487 patients with
PAD according to the four patient groups. Five-year
mortality rates were 10% in the 216 patients with
PAD <75 years of age without diabetes, 23% in the 115
patients with PAD <75 years with diabetes, 38% in the
102 patients with PAD $75 years without diabetes, and
52% in the 54 patients with PAD $75 years with diabetes.
In Fig 2, survival curves for cases vs control subjects are
depicted. Five-year mortality rates were higher in cases
than in control subjects in the study participants
<75 years of age without diabetes (10% vs 5%; RR, 2.15;
95% conﬁdence interval [CI], 1.60-4.34; P ¼ .042); in
the study participants <75 years of age with diabetes
(23% vs 7%; RR, 3.53; 95% CI, 1.80-6.91; P < .001);
and in the study participants $75 years of age without
diabetes (38% vs 22%; RR, 2.08; 95% CI, 1.26-3.44;
P ¼ .005). Table II summarizes the results in cases and
healthy control subjects.
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Fig 2. Kaplan-Meier plots show survival in (A) 216 nondiabetic
patients with peripheral arterial disease (PAD) <75 years of age
and 216 age- and sex-matched nondiabetic control subjects; (B) in
115 diabetic PAD patients with PAD <75 years of age and 115
age- and sex-matched diabetic control subjects; and (C) in 102
nondiabetic patients with PAD $75 years and 102 age- and sex-
matched nondiabetic control subjects. CI, Conﬁdence interval.
Table II. Rates of 5-year all-cause mortality in patients
with PAD and control subjects according to the four
patient groups
Patient groups
Total,
No. (%)
Decedents,
No. (%)
Survivors,
No. (%)
Nondiabetic patients with
PAD <75 years of age
216 (100) 21 (10) 195 (90)
Nondiabetic control
subjects <75 years of age
216 (100) 10 (5) 206 (95)
Diabetic patients with
PAD <75 years of age
115 (100) 26 (23) 89 (77)
Diabetic control subjects
<75 years of age
115 (100) 8 (7) 107 (93)
Nondiabetic patients with
PAD $75 years of age
102 (100) 39 (38) 63 (62)
Nondiabetic control
subjects
$75 years of age
102 (100) 22 (22) 80 (78)
Diabetic patients with PAD
$75 years of age
54 (100) 28 (52) 26 (48)
Diabetic control subjects
$75 years of age
-a -a -a
LIPAD, Linz Peripheral Arterial Disease; PAD, peripheral arterial disease.
aControl subjects without any relevant atherosclerotic disease matched to
the 54 diabetic patients with PAD $75 years of age were not enrolled into
the LIPAD study.
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Cox proportional hazards regression analyses are detailed.
In the 216 patients with PAD <75 years of age without
diabetes, hs-CRP was the only independent predictor of5-year mortality (RR, 3.04; 95% CI, 1.48-6.26; P ¼
.003). In the 115 patients with PAD <75 years of age
with diabetes, NT-proBNP was the only independent pre-
dictor of 5-year mortality (RR, 2.63; 95% CI, 1.65-4.19;
P < .001). In the 102 patients with PAD $75 years of
age without diabetes, both the presence of critical limb
ischemia (RR, 3.70; 95% CI, 1.82-7.52; P < .001) and
NT-proBNP (RR, 1.93; 95% CI, 1.32-2.82; P ¼ .001)
were independent predictors of mortality. In the 54 pa-
tients with PAD $75 years of age with diabetes, hs-CRP
(RR, 2.61; 95% CI, 1.45-4.67; P ¼ .001) and NT-
proBNP (RR, 3.31; 95% CI, 1.96-5.60; P < .001) contrib-
uted independently to mortality prediction.
DISCUSSION
The results of this study demonstrate that all-cause
mortality at 5 years varied considerably among symptomatic
patients with PAD stratiﬁed according to age and diabetes.
In patients with PAD <75 years of age, mortality rates were
10% in individuals without diabetes and 23% in individuals
with diabetes. In patients with PAD$75 years of age, mor-
tality rates were 38% in individuals without diabetes and
52% in individuals with diabetes. Compared with healthy
control subjects, the relative risk to die within 5 years was
2.0- to 3.5-fold in patients with symptomatic PAD. On
the basis of a linear association between survival probability
and time, the overall 5-year mortality rate of 23% obtained
for our entire PAD cohort implies an annual rate of death
from all causes of 4-5%, which is roughly comparable with
results on patients with PAD published previously.1,19
However, we found a wide span of annual mortality rates
among our subgroups of patients with PAD ranging from
Table III. Results of Cox proportional hazards regression analyzing the capability of the study variables for the prediction
of 5-year all-cause mortality according to the four patient groups
Predictor variables
Nondiabetic patients with PAD <75 years of age Diabetic patients with
n ¼ 216 (21 decedents vs 195 survivors) n ¼ 115 (26 decedents vs
Univariate
analyses
Multivariate
analysisa
Univariate
analyses
RR (95% CI); P RR (95% CI); P RR (95% CI); P
Ageb 1.85 (1.00-3.41); .049 n.e. 2.89 (1.42-5.90); .003
Male sex (vs female) 2.63 (0.61-11.3); .193 n.e. 1.10 (0.44-2.75); .834
Body mass indexb 0.88 (0.56-1.40); .602 n.e. 0.84 (0.58-1.20); .332
Arterial hypertension (vs not) 0.94 (0.40-2.24); .893 n.e. 3.28 (0.98-10.9); .053
Cardiovascular comorbidity (vs not) 2.45 (1.04-5.76); .041 n.e. 3.37 (1.35-8.40); .009
Current smoking (vs not) 1.05 (0.44-2.48); .920 n.e. 0.96 (0.44-2.09); .919
Critical limb ischemia (vs
claudication)
3.28 (1.20-8.97); .020 n.e. 2.84 (1.31-6.14); .008
Resting ABI 0.06 (0.01-0.37); .003 n.e. 0.85 (0.24-2.94); .792
History of PAD-speciﬁc
interventionc (vs not)
2.25 (0.95-5.34); .066 n.e. 1.17 (0.54-2.53); .685
PAD-speciﬁc intervention during
index hospitalizationd (vs not)
0.97 (0.38-2.49); .945 n.e. 0.85 (0.39-1.84); .673
eGFRb 0.85 (0.48-1.53); .588 n.e. 0.55 (0.40-0.77); .001
LDL-cholesterolb 0.76 (0.53-1.08); .121 n.e. 0.74 (0.53-1.04); .085
HDL-cholesterolb 0.99 (0.62-1.60); .981 n.e. 1.15 (0.80-1.66); .449
Triglyceridesb 0.82 (0.54-1.24); .339 n.e. 0.91 (0.61-1.36); .645
Fasting glucoseb 1.17 (0.34-4.05); .806 n.e. 0.85 (0.57-1.26); .411
Glycohemoglobin A1cb 0.66 (0.21-2.14); .491 n.e. 0.80 (0.53-1.20); .273
Adiponectinb 1.17 (0.74-1.86); .497 n.e. 1.38 (0.91-2.07); .127
Total homocysteineb 1.17 (0.79-1.73); .444 n.e. 1.24 (0.82-1.86); .302
hs-CRPb 3.04 (1.48-6.26); .003 3.04 (1.48-6.26); .003 1.58 (0.89-2.78); .116
NT-proBNPb 1.58 (1.01-2.48); .048 n.e. 2.63 (1.65-4.19); <.001
PAPP-Ab 1.46 (0.93-2.92); .099 n.e. 1.29 (0.95-1.76); .106
ABI, Ankle-brachial index; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-
reactive protein; LDL, low-density lipoprotein; n.e., not entered into the model (ie, stepwise entry limit of P < .01 was exceeded for each of these variables);
NT-proBNP, amino-terminal pro-Betype natriuretic peptide; PAD, peripheral arterial disease; PAPP-A, pregnancy-associated plasma protein-A; PTA,
percutaneous transluminal angioplasty with or without stenting; RR, risk ratio.
aMultivariate RRs were calculated with Cox proportional hazards regression analysis with the use of a conditional stepwise forward approach offering all
independent variables listed in the table. These variables were entered sequentially into the multivariate Cox proportional hazards regression analysis by
means of a stepwise entry limit of P < .01.
bContinuous variables were not normally distributed and were normalized by log transformation. RRs refer to a 1-standard deviation increase in log-
transformed values.
cHistory of PAD-speciﬁc intervention before index hospitalization was deﬁned as at least one of the following: vascular surgery, PTA, or amputation.
dPAD-speciﬁc intervention during index hospitalization was deﬁned as at least one of the following: vascular surgery, PTA, or amputation.
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1296 Mueller et al May 20142% in patients <75 years of age without diabetes to 10% in
patients with PAD $75 years of age with diabetes. There-
fore, mortality rates of patients with PAD strongly depend
on demographic features of the cohort studied such as age
distribution and diabetes mellitus status. This should be
considered in interpreting published results of outcome in
symptomatic PAD.
In our attempt to determine predictors of death, we
obtained only three independent predictor variables for
all-cause mortality at 5 years among symptomatic patients
with PAD stratiﬁed according to age and diabetes mellitus.
Although different in each of the four patient subgroups,
the signiﬁcant predictors of death at 5 years were the pres-
ence of critical limb ischemia as well as increased plasma
concentrations of hs-CRP and NT-proBNP. Our ﬁndings
could be of importance for clinical practice because speciﬁcstrategies for risk factor modiﬁcation in the four PAD sub-
groups might be justiﬁed to improve outcome.
hs-CRP has been evaluated on a limited basis as a prog-
nostic marker in patients with symptomatic PAD.7 On the
other hand, the role of inﬂammation in the development of
atherosclerosis and its predisposition for cardiovascular
events is established.20 Because CRP has a role in the
immunological process that promotes vascular remodeling
and plaque formation, it is considered to be a biomarker of
vascular inﬂammation and atherosclerosis.20,21 Further-
more, CRP is a putative marker for the assessment of
cardiovascular risk and the need for statin therapy, respec-
tively. In addition, CRP has been proposed to represent a
potential target of treatment.21 Increasing CRP plasma
concentrations are related to increased mortality and a
more rapid functional decline among individuals with
PAD <75 years of age Nondiabetic patients with PAD $75 years of age Diabetic patients with PAD $75 years of age
89 survivors) n ¼ 102 (39 decedents vs 63 survivors) n ¼ 54 (28 decedents vs 26 survivors)
Multivariate
analysisa
Univariate
analyses
Multivariate
analysisa
Univariate
analyses
Multivariate
analysisa
RR (95% CI); P RR (95% CI); P RR (95% CI); P RR (95% CI); P RR (95% CI); P
n.e. 1.96 (0.65-5.91); .231 n.e. 2.76 (0.70-11.0); .148 n.e.
n.e. 1.56 (0.83-2.94); .167 n.e. 1.73 (0.76-3.92); .193 n.e.
n.e. 0.88 (0.63-1.24); .471 n.e. 0.76 (0.46-1.26); .284 n.e.
n.e. 0.85 (0.44-1.65); .631 n.e. 0.53 (0.21-1.32); .171 n.e.
n.e. 1.19 (0.64-2.24); .058 n.e. 1.47 (0.68-3.18); .333 n.e.
n.e. 1.15 (0.55-2.43); .711 n.e. 0.43 (0.10-1.80); .247 n.e.
n.e. 5.15 (2.64-10.0); <.001 3.70 (1.82-7.52); <.001 3.67 (1.72-7.81); .001 n.e.
n.e. 1.32 (0.41-4.24); .641 n.e. 1.84 (0.47-7.23); .384 n.e.
n.e. 0.89 (0.46-1.70); .716 n.e. 1.15 (0.55-2.42); .704 n.e.
n.e. 0.38 (0.20-0.73); .004 n.e. 0.71 (0.34-1.50); .375 n.e.
n.e. 0.68 (0.51-0.89); .006 n.e. 0.69 (0.51-0.94); .019 n.e.
n.e. 0.60 (0.43-0.84); .002 n.e. 0.83 (0.55-1.25); .375 n.e.
n.e. 0.81 (0.57-1.16); .247 n.e. 0.55 (0.38-0.80); .002 n.e.
n.e. 0.84 (0.59-1.21); .348 n.e. 0.65 (0.43-1.00); .049 n.e.
n.e. 0.41 (0.14-1.17); .095 n.e. 1.16 (0.84-1.61); .368 n.e.
n.e. 0.81 (0.34-1.95); .633 n.e. 1.58 (1.05-2.37); .029 n.e.
n.e. 1.55 (1.06-2.26); .023 n.e. 1.22 (0.88-1.68); .226 n.e.
n.e. 1.82 (1.23-2.68); .003 n.e. 1.56 (0.92-2.64); .100 n.e.
n.e. 2.11 (1.39-3.20); <.001 n.e. 2.35 (1.36-4.06); .002 2.61 (1.45-4.67); .001
2.63 (1.65-4.19); <.001 2.32 (1.61-3.33); <.001 1.93 (1.32-2.82); .001 3.16 (1.92-5.22); <.001 3.31 (1.96-5.60); <.001
n.e. 0.94 (0.69-1.29); .716 n.e. 1.56 (0.99-2.48); .056 n.e.
Table III. Continued.
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high cardiovascular event rate in PAD and improves
impaired walking performance in PAD, most probably
because statins reduce inﬂammation.22 In addition, the
possibility has been raised that it might be an option to spe-
ciﬁcally target inﬂammatory pathways for the treatment of
cardiovascular disease (eg, by low-dose methotrexate or
adalimumab, canakinumab, tocilizumab, and others).23-25
However, no clinical trials have been published to establish
whether therapies that reduce CRP concentrations improve
outcomes in patients with PAD. Therefore, prospective
studies will be necessary to thoroughly clarify the possibility
that statin therapy or speciﬁc inhibition of inﬂammatory
pathways will reduce cardiovascular events and mortality,
especially in younger nondiabetic patients with symptom-
atic PAD.The members of the natriuretic peptide family BNP and
NT-proBNP are established markers for functional cardiac
impairment and are increased in symptomatic and asymp-
tomatic heart disease.26,27 The blood concentrations of
BNP and NT-proBNP increase in proportion to the severity
of cardiac disease,26,27 and BNP and NT-proBNP are
considered therapeutic targets.28-30 Among other applica-
tions for natriuretic peptide measurements, our previous
work revealed that the prognostic value of NT-proBNP is
of particular interest in patients with PAD.10 Herein we
revealed that NT-proBNP is independently associated
with long-term mortality in symptomatic PAD in general.
Our current work is a further step in improving risk predic-
tion in PAD because we stratiﬁed our patients according to
age and diabetes. Therefore, it is a relevant result of the pre-
sent study that NT-proBNP was an independent predictor
JOURNAL OF VASCULAR SURGERY
1298 Mueller et al May 2014of death in only three of our four PAD subgroups, namely
in the diabetic patients and the older patients without dia-
betes but not in the younger nondiabetic patients. In
contrast to the latter group, a high percentage of patients
may have unrecognized heart disease in the other three
PAD subgroups.7,31 However, to reliably establish a
possible beneﬁt of natriuretic peptide measurements in
PAD in terms of initiation of further diagnostic actions
and adequate therapeutic interventions to reduce cardiovas-
cular mortality, further studies are necessary to randomly
assign patients with PAD to those with and without BNP
or NT-proBNP measurements and to compare the actual
outcome in both study arms.10
The presence of critical limb ischemiadthe most severe
clinical stage of PADdcontributed independently to 5-
year all-cause mortality of our nondiabetic patients with
PAD $75 years of age. The ﬁnding that critical limb
ischemia is associated with worse outcome in PAD is in
accordance with the current evidence.7 In contrast, the
resting ABIda reliable indicator of hemodynamic severity
of PADdwas not related independently with outcome in
any of our PAD subgroups. Of note, only in univariate
analysis and in the group of patients with PAD <75 years
of age without diabetes, resting ABI was associated with
worse outcome. The resting ABI of patients with symp-
tomatic PAD does not necessarily provide reliable informa-
tion regarding the risk of adverse events,7 although an
abnormal resting ABI can identify a population with high
risk among otherwise healthy subjects,7,32 In this context,
it is important to annotate that ABI measurements were
obtained at patient enrollment into the study (ie, before
any PAD-speciﬁc intervention during the index hospitaliza-
tion) and that the ratio of patients with PAD with preced-
ing revascularization therapy was high in our cohort. Albeit
such previously and adequately performed interventions in-
crease the ABI, an initially high risk for all-cause mortality
remains in the patients concerned. This might be the expla-
nation of why the resting ABI was not an independent pre-
dictor in our cohort of patients with symptomatic PAD.
In three of our PAD subgroups, the cardiac marker
NT-proBNP was an independent outcome predictor
most probably because heart disease accounts for the rela-
tively high mortality rates in those same subgroups. This is
important because NT-proBNP represents a therapeutic
target, as mentioned previously. In contrast, patients with
PAD <75 years of age without diabetes do not have heart
disease to the same extent. Therefore, the predictive value
of NT-proBNP was less pronounced and, instead, hs-
CRPdreﬂecting the atherosclerotic burden in younger,
nondiabetic individualsdwas the only independent predic-
tor of all-cause mortality at 5 years. In this patient sub-
group, therapeutic strategies to reduce hs-CRP plasma
concentrations and thereby impede the atherosclerotic
continuum and might be favorable. With respect to clinical
outcome predictors, it is somewhat astonishing that critical
limb ischemia independently predicted all-cause mortality
at 5 years only in the subgroup of nondiabetic patients
with PAD $75 years of age. On the basis of the explorativenature of our study, we currently do not have a reasonable
explanation for this observation. Future studies will be
necessary to clarify this issue.
We acknowledge that the number of events in each of
our four PAD subgroups was low. For this reason, we
applied Cox regression models with a stepwise forward
approach. Although we believe that this approach is advan-
tageous in terms of clinical applicability of the results, it was
not possible to fully adjust multivariate analyses for all
possible confounders in each of the four PAD subgroups,
which is a limitation of our study. The LIPAD cohort
comprised 487 patients with symptomatic PAD; matched
control subjects, however, were only recruited for non-
diabetic patients and for diabetic patients <75 years of
age (n ¼ 433). This is a limitation as well, but, given our
very rigorous study design, it was not possible to enroll
the necessary 54 diabetic control subjects $75 years of
age without any relevant atherosclerosis, as outlined in
the Methods section. It is a further limitation of the LIPAD
study that the patients were a selected subgroup of the
overall PAD population, as detailed in the Methods section
(white patients admitted for inpatient diagnosis/treatment
of atherosclerotic PAD). Therefore, we are not able to
generalize our ﬁndings to nonwhite individuals, patients
with asymptomatic PAD, or nonhospitalized patients with
PAD. Last, we would like to emphasize that the LIPAD
study was a single-center study.
CONCLUSIONS
The goals of therapy in patients with symptomatic PAD
are twofold.1,2,33 First, with respect to the affected limbs,
the goal is to eliminate/reduce ischemic symptoms andd
in the last consequencedto avoid major amputation. How-
ever, the prognosis of patients with PAD quoad extremita-
tem is poorly described in the current literature.33-35 The
second goal of therapy in patients with PAD is to prevent
cardiovascular events (eg, myocardial infarction, stroke,
and death), which result from widespread atherosclerosis.
Therefore, prognostic factors of patients with PAD quoad
vitam gain importance, as outlined in the introduction of
this report. Accordingly, it might be of clinical relevance
that we found three independent predictors of all-cause
mortality at 5 years in our cohort of patients with symp-
tomatic PAD stratiﬁed according to age and diabetes,
namely, hs-CRP, NT-proBNP, and critical limb ischemia.
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